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Abstract
The herpes simplex virus type 1 (HSV-1) latency associated transcript (LAT) gene has anti-apoptosis activity that directly or indirectly enhances the virus’s reactivation phenotype in small animal models. The first 1.5 kb of the primary 8.3 kb LAT is sufficient and some or all of it is
necessary for LAT’s anti-apoptosis in transient transfection assays and for LAT’s ability to enhance the reactivation phenotype. Based on LAT’s
genomic sequence, the first 1.5 kb contains eight potential open reading frames (ORFs) defined as an ATG followed by an in frame termination
codon. In this study, point mutations were introduced into the ATGs of ORFs present in the 1.5 kb fragment of LAT. Mutagenesis of all eight
ATGs in LAT ORFs consistently reduced the anti-apoptotic activity of LAT in transiently transfected mouse neuroblastoma cells regardless of
whether apoptosis was induced by caspase 8 or caspase 9. Mutation of the six ATGs located in the stable intron sequences within the 1.5 kb
LAT had a dramatic effect on caspase 9, but not caspase 8, induced apoptosis. For both caspase 8 and caspase 9 induced apoptosis, mutating the
two ATGs in the exon of the LAT 1.5 kb fragment reduced, but did not eliminate the anti-apoptotic activity of LAT. These studies suggest that
altering the fine structure of regulatory RNA or expression of a putative LAT ORF regulates the anti-apoptosis activity of LAT. These studies
also indicate that more than one function is present in the 1.5 kb LAT fragment.
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As many as 90% of adults in the US harbor latent herpes
simplex virus type 1 or type 2 (HSV-1, HSV-2) infections
[1]. HSV-1 causes cold sores in and around the mouth, genital herpes, encephalitis, and corneal disease. In the US, HSV1 is the leading cause of corneal blindness due to an infectious agent [2]. HSV-1-induced corneal blindness is due to
scarring of the cornea, mostly in response to recurrent rather
than primary infection. Following a primary ocular HSV-1
infection the virus enters sensory nerves and travels to the
nerve bodies located in the trigeminal ganglia (TG). Here,

life long viral latency is established. Sporadic viral reactivations can occur throughout the life of the infected individual,
at which time virus returns to, is shed at the ocular surface,
and can cause recurrent disease leading to loss of vision. Understanding the molecular mechanisms by which the HSV-1
latency-reactivation cycle is regulated is therefore important
for the eventual control and elimination of recurrent herpetic
disease.
During neuronal latency the latency associated transcript,
or LAT gene, is the only abundantly transcribed viral gene [3
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& 4]. LAT plays an important role in the HSV latency-reactivation cycle since LAT null mutants have significantly reduced reactivation phenotypes in mice and rabbits while otherwise having wild-type like replication [5–11]. LAT has
anti-apoptosis activity [12–19]. Mutants in which LAT is replaced by an alternative anti-apoptosis gene have efficient,
wild-type like reactivation phenotypes [20–22], indicating
that LAT’s anti-apoptosis activity is sufficient to account for
LAT’s ability to support the wild-type reactivation phenotype
in experimental animal models.
The mechanism by which LAT’s anti-apoptosis activity enhances the reactivation phenotype remains to be elucidated. In addition, how LAT’s anti-apoptosis activity is mediated also remains to be fully elucidated. However, the most
critical LAT functions appear to be encoded within the first
1.5 kb of LAT, since the first 1.5 kb of the primary 8.3 kb primary LAT (approximately the first 18%) is sufficient for both
supporting a wild-type virus reactivation phenotype [23] and
for efficiently blocking apoptosis in transient transfection assays [13 & 16].
Based on sequence analysis of the LAT DNA, the first
1.5 kb of LAT contains eight potential open reading frames
(ORFs; an ATG followed by an in frame stop codon). However, the nucleotide sequence in this region is more highly
conserved among functional LATs from three different HSV1 strains ( > 95%) than are the predicted amino acid sequences (< 80%). This suggests that there is more selective
pressure to maintain the RNA sequence than protein coding
sequences, suggesting that this region of LAT does not en-
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code an important functional protein. We therefore proposed
that LAT functions via its RNA rather than via a LAT protein. Consistent with this, it was recently reported that LAT
encodes a miRNA that has anti-apoptosis activity [17]. However, this miRNA is unlikely to account for LAT’s full function as it is encoded from a location that is neither essential
for [15 & 24], nor sufficient for [13] LAT’s ability to block
apoptosis or enhance the reactivation phenotype. Thus, this
miRNA does not rule out the possibility of a LAT protein or
additional regulatory RNAs.
The work presented here was initiated in the hope of demonstrating that none of the potential eight LAT ORFs discussed above play a role in the ability of LAT to block apoptosis and by extension also not involved in LAT’s ability to
enhance the viral reactivation phenotype. Surprisingly, we report here that changing the relevant ATGs to TTGs to knock
out expression of these putative proteins had a significant impact on LAT’s anti-apoptosis activity.
We constructed three mutant LAT plasmids (Figure 1), the
parental plasmid of which (LAT3.3A) contains LAT nts −1801
to +1499 [13 & 23]. The presence of the entire LAT promoter
results in this plasmid expressing high levels of the first 1.5 kb
of LAT following transfection of tissue culture cells. It should
also be noted that LAT3.3A does not encode the entire stable
2 kb LAT intron, but still maintains high levels of anti-apoptosis activity. In plasmid LAT3.3E, the first two LAT ATGs
were mutated to TTG, thereby knocking out both of the potential ORFs located within the exon (LAT nts 1–660). In plasmid LAT3.3I, all six potential ORFs within the region of the

Figure 1. LAT-derived plasmids. (A) LAT3.3A, the parental plasmid, contains LAT nts −1801 to +1499 relative to the start of LAT transcription. It therefore contains the entire LAT promoter and upstream control sequences and transcribes the first 1.5 kb of the primary 8.3 kb LAT. Nts +1 to 661 correspond to the first
LAT exon. Nts 662–1499 correspond to the first 837 nts of the 2 kb stable LAT intron. The solid rectangles show the relative locations of all eight potential ORFs
(ATG followed by an in frame stop codon) within the first 1499 nts of the primary LAT transcript. The nt positions of the ORFs relative to the start of LAT transcription at LAT nt +1 are: ORF 1 = nts 217–376; ORF 2 = nts 486–669; ORF 3 = nts 916–1123; ORF 4 = 980–1079; ORF 5 = nts 1091–1298; ORF 6 = 1167–
1242; ORF 7 = 1279–1360; ORF 8 = 1365–1497 [29]. All of the other plasmids are identical to LAT3.3A except for knock out of various ORFs by mutation
of the relevant ATG to TTG by PCR site directed mutation. All changes were confirmed by complete sequencing of the final DNA fragments. (B) LAT3.3E is
knocked out for ORF 1 and ORF 2 in the exon but retains all six ORFs in the first 878 nts of the 2 kb intron. (C) LAT3.3I is knocked out for all six ORFs in the
intron but retains both ORFs in the exon. (D) LAT3.3U is knocked out for all eight ORFs.
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first 2 kb LAT that is located within the first 1.5 kb of the LAT
transcript (LAT nts 661–1499) were similarly knocked out. All
eight potential ORFs were similarly knocked out in LAT3.3U.
In mammals, there are two major apoptotic pathways; the
death receptor-mediated pathway or the mitochondrial pathway [25–27]. The receptor-mediated death pathway activates
caspase 8, which induces a caspase cascade including caspase
3. Activation of the mitochondrial death pathway results in release of several important proapoptotic molecules, including
cytochrome C and Smac/Diablo [27]. Released cytochrome C
associates with Apaf-1 leading to caspase 9 activation, which
culminates in activation of the effector caspases (including
caspase 3). Thus, it was important to compare the results obtained with caspase 8 induced apoptosis to those obtained by
inducing apoptosis with caspase 9.
Consequently, Neuro-2A cells were transfected with each
of the LAT plasmids plus a plasmid that induces apoptosis
by expressing caspase 8 (Figure 2). Cell survival was determined 48 h later as previously described [15 & 16]. The number of cells in control cultures transfected with the same total
amount of empty plasmid (no LAT; no caspase 8) was set to
100%. Approximately, 38% of cells survived with the caspase
8 plasmid alone. As we previously reported, LAT3.3A signif-

icantly protected against caspase 8 induced death (90% survival; P < 0.05 versus caspase 8, ANOVA two way analysis
of variance). LAT3.3E, LAT3.3I, and LAT3.3U all had significantly less survival than the control and LAT3.3A (P < 0.05).
LAT3.3U did not appear to provide any protection against
caspase 8 induced apoptosis (P > 0.05) and was significantly
different from all of the other plasmids (P < 0.05). LAT3.3E
and LAT3.3I both appeared to provide intermediate protection as they were each significantly different from the control, LAT3.3A, and caspase 8 (P < 0.05) but were not different
from each other (P > 0.05). Thus, knocking out either ORFs
1 and 2 (LAT3.3E), ORFs 3–8 (LAT3.3I), or all eight ORFs
appeared to reduce the protective effect of LAT against caspase 8 induced death. Knocking out all eight ORFs appeared
to more effectively prevent LAT’s anti-apoptosis activity than
knocking out just ORFs 1–2 or just ORFs 3–8.
To determine the effects of these ORF knockouts on caspase 9 induced apoptosis, experiments performed as above
were done using a caspase 9, rather than a caspase 8, expressing plasmid to induce apoptosis (Figure 3). Caspase 9 reduced cell survival to approximately 30% of the control. As
with caspase 8 induced apoptosis, the intact LAT3.3A plasmid efficiently blocked caspase 9 induced cell death (P < 0.05

Figure 2. Inhibition of caspase 8 induced apoptosis by LAT constructs. Using our standard apoptosis blocking assay [15 & 16] Neuro2A cells were cotransfected with a caspase 8 expressing plasmid to induce apoptosis and one
of the LAT expressing plasmids (LAT3.3A, LAT3.3E, LAT3.3I, or LAT3.3U).
Control cells were transfected with the same total amount of empty plasmid.
Caspase 8 cells were co-transfected with the caspase 8 plasmid and the same
amount of empty plasmid used in the various LAT samples. Each bar represents the average±S.E. of three independent experiments, each done at least
in triplicate.

Figure 3. Inhibition of caspase 9 induced apoptosis by LAT constructs. Experiments were done as described for Figure 2, except that a caspase 9 expressing plasmid was used instead of a caspase 8 expressing plasmid. Each
bar represents the average±S.E. of four independent experiments, each done
at least in triplicate.
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versus caspase 9). As with caspase 8 induced apoptosis, the
LAT3.3E plasmid, knocked out for the first two ORFs, provided intermediate protection. LAT3.3E provided significant
protection against caspase 9 induced apoptosis (P < 0.05),
but the protection was significantly less than that provided
by LAT3.3A (P < 0.05). In contrast to the caspase 8 results,
LAT3.3I was significantly different from LAT3.3E (P < 0.05)
and did not appear to provide any protection against caspase
9 induced apoptosis (P > 0.05). On the other hand, as for caspase 8 induced apoptosis LAT3.3U did not appear to provide
any protection against caspase 9 induced apoptosis. LAT3.3U
was not significantly different from caspase 9 (P > 0.05),
but was significantly different from the control, LAT3.3A,
or LAT3.3E (P < 0.05). Thus, as with protection against caspase 8 induced apoptosis, knocking out either ORFs 1 and
2, ORFs 3–8, or all eight ORFs, appeared to reduce the ability of LAT to interfere with apoptosis. Knocking out all eight
ORFs appeared to more effectively inhibit LAT’s anti-apoptosis activity compared to knocking out just the first two ORFs.
Knocking out just ORFs 1 and 2 produced intermediate protection, while knocking out all eight ORFs or just ORFs 3–8,
appeared to completely block LAT’s ability to block caspase
9 induced apoptosis.
The above results show that preventing or knocking out
potential protein synthesis from the 8 potential LAT ORFs located within the functional first 1.5 kb of LAT can reduce that
ability of a LAT plasmid to block apoptosis induced by either
caspase 8 or caspase 9. However, whether these results indicate that there is one of more LAT protein involved in LAT’s
anti-apoptosis activity remains unclear. These experiments
were undertaken with the expectation that knocking out the
LAT ORFs by introducing single nucleotide changes (ATG to
TTG) would have little or no impact on LAT’s anti-apoptosis
activity thus confirming that none of the eight potential LAT
proteins was critical for LAT’s anti-apoptosis activity and
hence LAT’s ability to enhance the reactivation phenotype.
If interpretation of the results are artificially restricted
only to effects on translation of potential LAT proteins, one
would have to conclude that LAT encodes at least two proteins, one from the exon (ORFs 1 or 2) and one from the beginning of the 2 kb intron (ORFs 3–8). However, other explanations are at least as likely. The single nucleotide changes
may have affected the overall structure of the LAT RNA thus
reducing an anti-apoptosis activity that is mediated by a large
portion of the first 1.5 kb of LAT. The changes may have affected stability of the transcript thus decreasing the steady
state amount of functional LAT product, regardless of its nature. However, this is unlikely because of the differential effect of LAT3.3I on caspase 8 versus caspase 9 induced apoptosis. Alternatively, LAT may encode numerous miRNAs or
other small RNAs that have a cumulative affect on suppressing apoptosis. Although none of the mutations introduced
overlap with the first LAT miRNA reported [17], we have detected two additional small LAT-derived RNAs both of which
would be affected by the introduced mutations (unpublished).
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It is also possible that one or more as yet undetected small
splices could fuse some of the ORFs together to generate a
larger functional protein.
Finally, the ability to block apoptosis induced by caspase
8 versus caspase 9 appeared similar for each of the plasmids
except LAT3.3I. This plasmid which is knocked out for ORFs
3–8 provided partial protection against caspase 8 induced
apoptosis that was similar to the level of protection provided
by LAT3.3E, which is knocked out for ORFs 1 and 2. In contrast, LAT3.3I provided no apparent protection against caspase 9 induced apoptosis. This suggests that within the first
1.5 kb of LAT, different LAT regions interfere with apoptosis
by influencing different parts of the apoptotic pathways.
Inhibiting apoptosis appears to be the most important LAT
function involved in enhancing the virus’ reactivation phenotype since we have shown that two different anti-apoptosis genes can restore the wild-type reactivation phenotype to
a LAT negative virus [20–22 & 28]. Determining if LAT interferes (directly or indirectly) with apoptosis via its RNA or
via a LAT protein is important to deciphering the molecular
mechanism(s) by which LAT inhibits apoptosis, thereby enhancing the viral reactivation phenotype. This in turn will be
important for developing a highly efficacious clinical intervention against HSV-1 reactivation and recurrent disease. Regardless of the exact mechanism, the results reported here indicate that very minor changes to the LAT sequence can result
in significant changes to LAT’s anti-apoptosis activity.
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